Spaulding Clinical Research Announces Collaboration with Blinded Diagnostics for Centralized Cardiac Safety Services for Select Pharmaceutical Clients
"We are very pleased with the relationship that we have built with Blinded Diagnostics. They are a knowledgeable and professional organization and will represent Spaulding's unique service offerings well. We are confident in their ability to deliver customer-focused solutions to this select group of pharmaceutical companies," states Kevin Geno, VP of Sales and Marketing for Spaulding Clinical Research.
"The Spaulding Model 1000iQ Electrocardiograph is an innovative and effective point of care 12-lead ECG device for use in clinical trials..." states Steve Karuppan, CEO of Blinded Diagnostics, "and we are particularly impressed by the Spaulding webECG data storage capability, analysis solutions and connectivity features for use in centralizing cardiac safety data from phase II-IV global trials."
About Spaulding Clinical Research, LLC
Spaulding Clinical Research, LLC (www.spauldingclinical.com) provides Clinical Pharmacology, Cardiac Core Lab clinical research services, and is a medical device manufacturer. Spaulding Clinical operates a 155-bed clinical pharmacology unit with 96-beds of telemetry in West Bend, Wisconsin, USA. The facility is paperless, with a Phase I Electronic Data Capture system and bidirectional interfaces to safety lab, bedside devices and telemetry. As a Phase I-IV Core ECG Laboratory provider, Spaulding Clinical offers the complete suite of equipment provisioning and electrocardiograph over-reading services with state-of-the-art technologies, including the proprietary Spaulding Model 1000iQ Electrocardiograph, expertly-cardiologists and project managers.